BCM
GNMX

BlueCrest Capital Management’s Aevi Genomic Medicine Inc GNMX Stock Holding History

BlueCrest Capital Management’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-14,901
Closed -$120K – 979
2015
Q1 		$120K Buy
+14,901
New +$112K 0.01% 584

Other funds holding GNMX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BlueCrest Capital Management's GNMX Position: Q2 2015 in Review

BlueCrest Capital Management sold out of Aevi Genomic Medicine Inc (GNMX) in Q2 2015, closing a stake of 14,901 shares — an estimated $120K sold.

BlueCrest Capital Management first reported a position in GNMX in Q1 2015 and held it in 1 quarter. The position peaked at $120K in Q1 2015. 54 funds tracked by Wall St. Rank hold GNMX as of Q2 2015.

  • BlueCrest Capital Management reported no remaining Aevi Genomic Medicine Inc position as of Q2 2015 after selling out during the quarter.
  • BlueCrest Capital Management sold 14,901 Aevi Genomic Medicine Inc shares in Q2 2015, an estimated $120K.
  • BlueCrest Capital Management first reported a position in Aevi Genomic Medicine Inc in Q1 2015 and held it in 1 quarter.
  • BlueCrest Capital Management's Aevi Genomic Medicine Inc position peaked at $120K in Q1 2015.
  • 54 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q2 2015.

Based on BlueCrest Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.